222 related articles for article (PubMed ID: 1327922)
21. Inotropic therapy of heart failure. Editorial comments on: Vasodilation and mechanoenergetic inefficiency dominates the effect of the "Ca2+ sensitizer" MCI-154 in intact pigs.
Duncker DJ; Verdouw PD
Scand Cardiovasc J; 2002 May; 36(3):131-5. PubMed ID: 12079634
[No Abstract] [Full Text] [Related]
22. Phosphodiesterase inhibitors as tools in cyclic nucleotide research: a precautionary comment.
Wells JN; Kramer GL
Mol Cell Endocrinol; 1981 Jul; 23(1):1-9. PubMed ID: 6167475
[No Abstract] [Full Text] [Related]
23. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta.
Lugnier C; Schoeffter P; Le Bec A; Strouthou E; Stoclet JC
Biochem Pharmacol; 1986 May; 35(10):1743-51. PubMed ID: 2423089
[TBL] [Abstract][Full Text] [Related]
24. [Phosphodiesterase III inhibitor--characteristics, mechanisms of action, pharmacokinetics, indications, contraindications, clinical trials, and side effects].
Sato N
Nihon Rinsho; 2007 May; 65 Suppl 5():43-8. PubMed ID: 17571364
[No Abstract] [Full Text] [Related]
25. Rabbit corpus cavernosum smooth muscle shows a different phosphodiesterase profile than human corpus cavernosum.
Qiu Y; Kraft P; Lombardi E; Clancy J
J Urol; 2000 Sep; 164(3 Pt 1):882-6. PubMed ID: 10953172
[TBL] [Abstract][Full Text] [Related]
26. Cyclic AMP-specific phosphodiesterase inhibitor rolipram and RO-20-1724 promoted apoptosis in HL60 promyelocytic leukemic cells via cyclic AMP-independent mechanism.
Zhu WH; Majluf-Cruz A; Omburo GA
Life Sci; 1998; 63(4):265-74. PubMed ID: 9698035
[TBL] [Abstract][Full Text] [Related]
27. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
Chen HH; Huntley BK; Schirger JA; Cataliotti A; Burnett JC
J Am Soc Nephrol; 2006 Oct; 17(10):2742-7. PubMed ID: 16928803
[TBL] [Abstract][Full Text] [Related]
28. Mechanism by which psychotropic drugs inhibit adenosine cyclic 3',5'-monophosphate phosphodiesterase of brain.
Levin RM; Weiss B
Mol Pharmacol; 1976 Jul; 12(4):581-9. PubMed ID: 183095
[No Abstract] [Full Text] [Related]
29. Effects of isoenzyme-selective inhibitors of cyclic nucleotide phosphodiesterase on microvascular leak in guinea pig airways in vivo.
Raeburn D; Karlsson JA
J Pharmacol Exp Ther; 1993 Dec; 267(3):1147-52. PubMed ID: 8263775
[TBL] [Abstract][Full Text] [Related]
30. Analysis of the relationship between pharmacological inhibition of cyclic nucleotide phosphodiesterase and relaxation of canine tracheal smooth muscle.
Polson JB; Krzanowski JJ; Anderson WH; Fitzpatrick DF; Hwang DP; Szentivanyi A
Biochem Pharmacol; 1979 Apr; 28(8):1391-5. PubMed ID: 87201
[No Abstract] [Full Text] [Related]
31. Inhibition cyclic nucleotide phosphodiesterase by FPL 55712, an SRS-A antagonist.
Chasin M; Scott C
Biochem Pharmacol; 1978; 27(16):2065-7. PubMed ID: 214090
[No Abstract] [Full Text] [Related]
32. Inhibition of human lung cyclic GMP and cyclic AMP phosphodiesterases by certain nucleosides, nucleotides, and pharmacological phosphodiesterase inhibitors.
Glass WF; Moore JB
Biochem Pharmacol; 1979 Apr; 28(7):1107-12. PubMed ID: 87197
[No Abstract] [Full Text] [Related]
33. Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation.
Rybalkin SD; Bornfeldt KE
Thromb Haemost; 1999 Aug; 82(2):424-34. PubMed ID: 10605733
[No Abstract] [Full Text] [Related]
34. Selective alteration of Ca2+-dependent and Ca2+-independent cyclic nucleotide phosphodiesterase activity in rat cerebral cortex by cyclic nucleotides and their analogs.
Davis CW
Biochim Biophys Acta; 1982 Jul; 705(1):1-7. PubMed ID: 6288105
[TBL] [Abstract][Full Text] [Related]
35. Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity.
Ahn HS; Bercovici A; Boykow G; Bronnenkant A; Chackalamannil S; Chow J; Cleven R; Cook J; Czarniecki M; Domalski C; Fawzi A; Green M; Gündes A; Ho G; Laudicina M; Lindo N; Ma K; Manna M; McKittrick B; Mirzai B; Nechuta T; Neustadt B; Puchalski C; Pula K; Zhang H
J Med Chem; 1997 Jul; 40(14):2196-210. PubMed ID: 9216839
[TBL] [Abstract][Full Text] [Related]
36. Species-dependent pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 58993 and WIN 62005.
Dundore RL; Pagani ED; Bode DC; Bacon ER; Singh B; Lesher GY; Buchholz RA; Silver PJ
J Cardiovasc Pharmacol; 1995 Jan; 25(1):14-21. PubMed ID: 7723343
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of human lymphocyte cyclic nucleotide phosphodiesterases by the chlorinated adenosine analog DTA-35.
Hurwitz MY; Hurwitz RL; Edstrom RD
J Enzyme Inhib; 1987; 1(4):267-74. PubMed ID: 2854846
[TBL] [Abstract][Full Text] [Related]
38. Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism.
Ahn HS; Eardley D; Watkins R; Prioli N
Biochem Pharmacol; 1986 Apr; 35(7):1113-21. PubMed ID: 2421728
[TBL] [Abstract][Full Text] [Related]
39. Selective inhibition of rat lung cyclic AMP phosphodiesterase and cyclic GMP phosphodiesterase by cyclic nucleotides and their analogues and various drugs [proceedings].
Butt NM; Saeed SA; Collier HO
Biochem Soc Trans; 1980 Jun; 8(3):380-1. PubMed ID: 6249674
[No Abstract] [Full Text] [Related]
40. Dihydro- and tetrahydroisoquinolines as inhibitors of cyclic nucleotide phosphodiesterases from dog heart. Structure-activity relationships.
Van Inwegen RG; Salaman P; St Georgiev V; Weinryb I
Biochem Pharmacol; 1979 Apr; 28(8):1307-12. PubMed ID: 87199
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
